There is some evidence for the stronger induction of CSCs by HIF-1α in hypoxic areas during tumor development, and for HIF-2α as the main HIF factor under normoxic conditions that follow after cancer therapy, leading to a reduction in tumor size [80]. This evidence concerns the gene HIF1A and cancer.